A phase 3 trial evaluated the overall survival (OS) of patients with advanced melanoma treated with nivolumab combined with ipilimumab, nivolumab alone, or ipilimumab alone. The study found that nivolumab plus ipilimumab significantly improved OS compared to ipilimumab alone, with 58% of patients surviving for 3 years in the combination group versus 34% in the ipilimumab group. Nivolumab alone also showed better OS than ipilimumab, with 52% of patients surviving for 3 years. The median OS was 37.6 months in the nivolumab group and 19.9 months in the ipilimumab group. The combination therapy also showed a higher objective response rate and better progression-free survival. The safety profile was similar to previous reports, with treatment-related adverse events occurring in 59% of the combination group, 21% of the nivolumab group, and 28% of the ipilimumab group. The trial was conducted in 137 sites across 21 countries and enrolled 1296 patients. The results showed that combination therapy with nivolumab and ipilimumab provided significantly longer OS than ipilimumab alone, with the combination group showing numerically higher survival rates in most subgroups. The study highlights the effectiveness of combination therapy in improving survival outcomes for patients with advanced melanoma.A phase 3 trial evaluated the overall survival (OS) of patients with advanced melanoma treated with nivolumab combined with ipilimumab, nivolumab alone, or ipilimumab alone. The study found that nivolumab plus ipilimumab significantly improved OS compared to ipilimumab alone, with 58% of patients surviving for 3 years in the combination group versus 34% in the ipilimumab group. Nivolumab alone also showed better OS than ipilimumab, with 52% of patients surviving for 3 years. The median OS was 37.6 months in the nivolumab group and 19.9 months in the ipilimumab group. The combination therapy also showed a higher objective response rate and better progression-free survival. The safety profile was similar to previous reports, with treatment-related adverse events occurring in 59% of the combination group, 21% of the nivolumab group, and 28% of the ipilimumab group. The trial was conducted in 137 sites across 21 countries and enrolled 1296 patients. The results showed that combination therapy with nivolumab and ipilimumab provided significantly longer OS than ipilimumab alone, with the combination group showing numerically higher survival rates in most subgroups. The study highlights the effectiveness of combination therapy in improving survival outcomes for patients with advanced melanoma.